• Facebook
  • Twitter
  • Youtube
  • LinkedIn
  • eSTEP
  • MEMBERSHIP
  • CONTACT
  • SUPPORT US
THE VOICE OF STROKE IN EUROPE
European Stroke Organisation
  • About
    • What we do
    • Who we are
      • Leadership
      • ESO Committees
      • Honorary Members & Awards Selection Committee
      • Young Stroke Physicians and Researchers Committee
      • Head Office
    • Membership
      • Benefits
      • Individual Membership
      • Organisational Membership
      • Membership Fees
    • Governance
      • Bylaws and Statues, Advocacy
      • Code of Conduct
    • History
    • Global Stroke Cooperation
  • Blog
  • Meetings
    • ESO Conference
    • Winter School
    • Summer School
      • ESO Summer School 2023
    • Edinburgh Stroke Research Workshop
    • Garmisch Stroke Science Workshop
    • Focused Workshop
      • ESO Focused Workshop 2023
    • Educational Webinars
    • ESO Endorsed Meetings and Education
      • Applications for Endorsement
    • Events Calendar
  • Guidelines
    • ESO Guideline Directory
    • ESO Guideline Board
    • ESO Guideline Development Webinar
    • ESO Guideline Webinar
  • Projects
    • ANGELS
      • Aims and Objectives
      • European Angels Committee
      • How to Qualify
    • ESO EAST (Enhancing and Accelerating Stroke Treatment)
      • RES-Q — Registry of Stroke Care Quality
    • QASC
    • Stroke Action Plan
    • Stroke Unit and Stroke Centre Certification
    • WISE
  • Resources
    • eSTEP
    • European Master Programme in Stroke Medicine
    • Department to Department Visit Programme
    • Trials Network Committee
    • European Telestroke Networks
    • Paper of the Month
    • COVID-19 Resources
    • Task Force 4 Ukraine
  • Media
    • European Stroke Journal (ESJ)
    • Newsletter
    • Press
  • Search
  • Menu Menu

Atrial Cardiopathy and Stroke Prognosis

Lina Palaiodimou, MD

Second Department of Neurology, “Attikon” University Hospital, National and Kapodistrian University of Athens, Greece

Twitter: @LinaPalaiodimou

Original article: Prognostic significance of atrial cardiopathy in patients with acute ischemic stroke. European Stroke Journal. DOI: 10.1177/23969873221126000

ESJ - European Stroke Journal

Atrial cardiopathy constitutes of several functional and/or structural disorders of the left atrium, including – but not limited to – fibrosis, low atrial appendage ejection velocity, left atrial hypertrophy and enlargement, and, finally, atrial fibrillation (AF) development. Not surprisingly, several markers of atrial cardiopathy have been incorporated in risk stratification scores, such as the PROACTIA score, that may be used in clinical practice for the selection of post-stroke patients that could benefit from more prolonged cardiac rhythm monitoring for AF detection. Yet, atrial cardiopathy has also been related with ischemic stroke occurrence, regardless of clinically apparent AF, underscoring the presence of thromboembolic risk due to abnormal atrial substrates even before AF develops.

In the present study, the investigators assessed different atrial cardiopathy markers, including increased P-wave terminal force in V1 (PTFV1), advanced interatrial block (aIAB), prolonged P-wave duration, prolonged P-wave dispersion, paroxysmal supraventricular tachycardia, premature atrial contractions, prolonged PR interval, and severe left atrial enlargement, in a large cohort of 14,146 patients with acute ischemic stroke, derived from a nationwide, prospective registry in China, the Third China National Stroke Registry. Through multivariable analysis, an independent association of increased PTFV1 and aIAB with all-cause mortality at 1-year post-stroke emerged (adjusted HR 1.70; 95% CI: 1.18–2.45 and adjusted HR 1.47; 95% CI: 1.14–1.91, respectively). Importantly, this association remained significant even after excluding the patients that had AF (either previously known or newly detected during hospitalization). Furthermore, stroke patients with both those markers presented higher all-cause mortality compared to patients that had only one or none of the two markers (log-rank test, p < 0.01).

When vascular mortality was assessed, PTFV1 was found to be the only associated biomarker in the subset of patients that were not diagnosed with AF (adjusted HR 2.03; 95% CI: 1.13–3.66).

In addition, increased PTFV1 was also related with stroke recurrence at 1 year among the total population (adjusted HR 1.54; 95% CI: 1.22–1.96), with this significant association persisting even after patients with AF were excluded.

Following these results, the investigators proceeded with adding those atrial cardiopathy markers in the iScore and in the Essen Stroke Risk Score and found that the ability of these scores in predicting mortality and ischemic stroke recurrence, respectively, was slightly improved.

This is the largest to-date study, based on prospectively collected data, that depicts the association of atrial cardiopathy markers with post-stroke mortality and stroke recurrence, irrespective of AF detection. Whether the routine screening and evaluation of these atrial cardiopathy markers could trigger further management strategies (such as intensifying AF monitoring, reducing the potential thromboembolic risk or halting the progression of atrial cardiopathy) and ultimately lead to improvement of stroke prognosis remain to be elucidated.

—

Conflict of interest statement

Dr. Palaiodimou reports no conflicts of interest.

 

ESOC is Europe’s leading forum for advances in research and clinical care of patients with cerebrovascular diseases. ESOC 2023 will live up to its expectation, and present to you a packed, high quality scientific programme including major clinical trials, state-of-the-art seminars, educational workshops, scientific communications of the latest research, and debates about current controversies. ESOC 2023 preliminary programme is now available, and registration and abstract submission will open on 2 November 2022. Learn more here.

Recent Posts

  • Telestroke Online Workshop „Quality management in telestroke” 30/03/2023
  • D2D Visit Report – Dr Khachik Petrosyan 24/03/2023
  • D2D Visit Report – Meri Grigoryan 17/03/2023
  • Interview with Prof Götz Thomalla, University Medical Center Hamburg-Eppendorf, Germany, on the results of the ANGEL-ASPECT and SELECT2 trials 11/03/2023
  • D2D Visit Report – Solomiia Bandrivska 03/03/2023
  • 24 February 2023: Statement from the ESO Executive Committee on the situation in Ukraine 24/02/2023
  • 10TH ESO/ESMINT/ESNR STROKE WINTER SCHOOL – 10 Years of Shaping Europe’s Stroke Care 24/02/2023
  • Improving Care for our Patients with Intracerebral Haemorrhage: Time to ACT 17/02/2023
  • Transient Focal Neurologic Episodes and Cerebral Amyloid Angiopathy 10/02/2023
  • Slow-flow in acute ischaemic stroke 03/02/2023

Tags

2021 acute ischemic stroke Bern brain clinical COVID-19 D2D department to department visit emergency medicine ESJ ESO ESO-EAST ESOC ESOC 2018 ESOC 2019 ESOC 2022 ESOC2022 ESOWSO2020 Europe European Stroke Journal FESO guidelines hospital interview ischaemic stroke ischemic stroke networking Neurology newsletter RES-Q research SAFE stroke stroke care stroke in the young stroke research stroke treatment stroke trials summer school Switzerland TIA trials virtual WISE YSPR

Archive

Categories

  • ESO
  • ESOC
  • IRT Post
  • Stroke Research

European Stroke Organisation
Reinacherstrasse 131
4053 Basel / Switzerland
E: esoinfo@eso-stroke.org

  • Home
  • Membership
  • About ESO
  • Newsletter
  • ESO-Blog
  • Press
  • Task Force 4 Ukraine
  • my ESO
© ESO-STROKE 2020 — the Voice of Stroke in Europe
  • Facebook
  • Twitter
  • Youtube
  • LinkedIn
  • Imprint
  • Privacy Statement
  • Disclaimer
  • Contact
  • Sitemap
TF4UKR D2D Visiting Programme Application OpenESJ Young Reviewer Programme Application Open
Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsSettings

Cookie and Privacy Settings



How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.

Google Analytics Cookies

These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.

If you do not want that we track your visit to our site you can disable tracking in your browser here:

Other external services

We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Google reCaptcha Settings:

Vimeo and Youtube video embeds:

Other cookies

The following cookies are also needed - You can choose if you want to allow them:

Privacy Policy

You can read about our cookies and privacy settings in detail on our Privacy Policy Page.

Privacy Statement
Accept settingsHide notification only
Open Message Bar